Guaiacol
drugOn this page
Also known as (mu)-methoxyphenolCreodonFEMA NO. 2532GuaiastilNSC-3815O-guaiacolO-hydroxyanisolePyroguaiac acidSID17388828SID17389094SID49825822SID17389539SID144204582SID144210188SID144208334SID144213965
Summary
Guaiacol (CHEMBL13766) is a phase-3 clinical-stage small-molecule EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; indicated across 1 condition.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 1 condition
- Clinical trials: 2
- Chemistry: 124.14 Da · C7H8O2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL13766 |
| Name | Guaiacol |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 460 |
| ChEBI | CHEBI:28591 |
| Molecular formula | C7H8O2 |
| Molecular weight | 124.14 |
| InChIKey | LHGVFZTZFXWLCP-UHFFFAOYSA-N |
SMILES: COC1=CC=CC=C1O
IUPAC name: 2-methoxyphenol
ChEBI definition: A monomethoxybenzene that consists of phenol with a methoxy substituent at the ortho position.
Pharmacological roles (ChEBI): expectorant, disinfectant, EC 1.1.1.25 (shikimate dehydrogenase) inhibitor.
Other ChEBI roles (chemical / environmental): plant metabolite.
Also known as: (mu)-methoxyphenol, Creodon, FEMA NO. 2532, Guaiacol, Guaiastil, NSC-3815, O-guaiacol, O-hydroxyanisole, Pyroguaiac acid, guaiacol, SID17388828, SID17389094
Parent form; salt/anhydrous children: CHEMBL224145
Patent coverage: 22,419 distinct patent families (50,019 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 49,907 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Thyrotropin receptor, Beta-lactamase, Carbonic anhydrase 2, Carbonic anhydrase 1, Cellular tumor antigen p53, Lethal factor.
Bioactivity
ChEMBL activities: 6 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| TP53 | 7.9 | Potency | 12.6 | nM | CHEMBL_ACT_4878519 |
| P15917 | 6 | Potency | 1000 | nM | CHEMBL_ACT_4655733 |
| CA2 | 5.53 | Ki | 2940 | nM | CHEMBL_ACT_2415239 |
| TSHR | 5.3 | Potency | 5012 | nM | CHEMBL_ACT_3925177 |
| TSHR | 5.3 | Potency | 5012 | nM | CHEMBL_ACT_4702799 |
| P00811 | 5.25 | Potency | 5623 | nM | CHEMBL_ACT_4738823 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4).
The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.
Clinical trials
Total trials: 2.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01119534 | PHASE3 | UNKNOWN | Comparative Efficacy of the Suppository Versus Guaiacol Suppository Versus Guaifenesin Syrup in Pediatric Patients With Cough Due the Infectious Origin |
| NCT02581397 | PHASE3 | TERMINATED | Transpulmin Suppository and Guaiacol Compared to Transpulmin Syrup in Pediatric Participants With Productive Cough |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.